<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629559</url>
  </required_header>
  <id_info>
    <org_study_id>4D-310-C002</org_study_id>
    <nct_id>NCT05629559</nct_id>
  </id_info>
  <brief_title>4D-310 in Adults With Fabry Disease and Cardiac Involvement</brief_title>
  <official_title>An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4D Molecular Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4D Molecular Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter, open-label, dose-escalation trial to assess the safety,&#xD;
      tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study&#xD;
      population is comprised of adult males and females with Fabry Disease and cardiac involvement&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter, open-label, dose-escalation trial to assess the safety,&#xD;
      tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study&#xD;
      population is comprised of adult males and females with Fabry Disease and cardiac involvement&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2022</start_date>
  <completion_date type="Anticipated">May 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence and severity of adverse events following a single IV dose of 4D-310</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum AGA activity</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline in serum AGA activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum globotriaosylsphingosine (lysoGb3)</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline serum globotriaosylsphingosine (lysoGb3)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4D-310 Dose Level 1 - AAV NAb Titer Group A patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 1 - AAV NAb Titer Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4D-310 Dose Level 1 - AAV NAb titer Group B patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion cohort of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4D-310</intervention_name>
    <description>Single IV administration of 4D-310 Dose Level 1</description>
    <arm_group_label>4D-310 Dose Level 1 - AAV NAb Titer Group B</arm_group_label>
    <arm_group_label>4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4D-310</intervention_name>
    <description>Single IV administration of 4D-310 Dose Level 2</description>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4D-310</intervention_name>
    <description>Single IV administration of 4D-310 at the selected dose</description>
    <arm_group_label>4D-310 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males and females&#xD;
&#xD;
          2. Pathogenic GLA mutation consistent with Fabry Disease&#xD;
&#xD;
          3. Confirmed diagnosis of classic or late-onset Fabry disease with cardiac involvement&#xD;
&#xD;
          4. Individuals on ERT must be on a stable dose for at least 6 months (and a minimum of 12&#xD;
             months total exposure) prior to study enrollment&#xD;
&#xD;
          5. Agree to use highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of high titer neutralizing antibody to 4D-310 capsid, or presence of high&#xD;
             antibody titer to AGA&#xD;
&#xD;
          2. eGFR &lt;45 mL/min/1.73 m2&#xD;
&#xD;
          3. Undergone kidney transplantation or currently on hemodialysis or peritoneal dialysis&#xD;
&#xD;
          4. HIV, active or chronic hepatitis B or C,&#xD;
&#xD;
          5. Evidence of liver disease, severe pulmonary disease or diabetes with poor glycemic&#xD;
             control&#xD;
&#xD;
          6. History of stroke or transient ischemic attack within the last 12 months, or other&#xD;
             significant thromboembolic disease history (e.g. pulmonary embolism)&#xD;
&#xD;
          7. Contraindication to systemic corticosteroid therapy or immunosuppressive therapy&#xD;
&#xD;
          8. Chronic steroid use, defined as â‰¥ 3 months of oral corticosteroid use within the last&#xD;
             12 months.&#xD;
&#xD;
          9. Moderately severe to severe cardiovascular disease or uncontrolled hypertension&#xD;
&#xD;
         10. Left ventricular ejection fraction of &lt;45% on echocardiogram (ECHO)&#xD;
&#xD;
         11. Currently receiving investigational drug, device or therapy or having ever received&#xD;
             gene therapy&#xD;
&#xD;
         12. History of infusion related response to ERT or any adverse reaction leading to ERT&#xD;
             discontinuation&#xD;
&#xD;
         13. History of cancer within 2 years (exceptions include non-melanoma skin cancer,&#xD;
             localized prostate cancer treated with curative intent)&#xD;
&#xD;
         14. Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitra Tavakkoli, MD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>4D Molecular Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>January 30, 2023</last_update_submitted>
  <last_update_submitted_qc>January 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Nervous System Brain Diseases</keyword>
  <keyword>Metabolic</keyword>
  <keyword>Inborn Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Cerebral Small Vessel Diseases</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>X-Linked</keyword>
  <keyword>Inborn</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Sphingolipidoses</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Inborn Errors</keyword>
  <keyword>Lipodoses</keyword>
  <keyword>Lipid Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

